For millions of people, the miracle of GLP-1 weight-loss drugs comes with a daunting caveat: the fear of the “rebound.” While medications like Ozempic and Mounjaro have revolutionized metabolic health, they have also created a new clinical dilemma—a dependency where discontinuing the drug often leads to regaining a significant portion of the lost weight. However, … Read more
Eli Lilly’s Foundayo Receives FDA Approval, Intensifying Competition in Weight Loss Medications In a significant development for individuals managing obesity and related health conditions, the Food and Drug Administration (FDA) has granted approval to Eli Lilly’s Foundayo (orforglipron), an oral glucagon-like peptide-1 (GLP-1) receptor agonist. This approval arrives approximately three months after Novo Nordisk introduced … Read more
Cuban and eMed Challenge Direct-to-Consumer GLP-1 Drug Models at SXSW March 15, 2026 Austin, TX – A sharp contrast in philosophies regarding access to GLP-1 medications emerged at South by Southwest (SXSW) this week, as Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of eMed Population Health, publicly differentiated their approaches from … Read more
The burgeoning class of drugs initially designed to combat diabetes and obesity – semaglutide, tirzepatide, and others – are rapidly rewriting the landscape of metabolic health. But their influence doesn’t stop there. A groundbreaking analysis of over 600,000 veterans’ health records suggests a remarkable, and potentially paradigm-shifting, side effect: a significant reduction in the risk … Read more